Key clinical point: Noncachexic patients with advanced nonsmall cell lung cancer (NSCLC) and adipose tissue loss may respond more favorably to immunotherapy.

Major finding: Cachexic patients with loss and maintenance of adipose tissue showed no significant differences in the objective response rate (ORR) and progression-free survival (PFS). Noncachexic patients with loss vs maintenance of adipose tissue demonstrated a higher ORR (64.7% vs 23.5%; P < .05) and longer PFS (18.5 vs 2.86 months; P = .037) in response to immunotherapy.

Study details: The data come from a single-center retrospective cohort study involving patients with advanced NSCLC (40 with cachexia and 34 without cachexia) who received programmed cell death-1/programmed cell death-ligand 1 inhibitors (pembrolizumab, nivolumab, or atezolizumab).

Disclosures: The study was funded by the Japan Agency for Medical Research and Development. The authors reported ties with one or more pharmaceutical companies outside this work.

Source: Nishioka N et al. Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer. Thorac Cancer. 2022;13(10):1496-1504 (Apr 14). Doi: 10.1111/1759-7714.14421

Key clinical point: Noncachexic patients with advanced nonsmall cell lung cancer (NSCLC) and adipose tissue loss may respond more favorably to immunotherapy.

Major finding: Cachexic patients with loss and maintenance of adipose tissue showed no significant differences in the objective response rate (ORR) and progression-free survival (PFS). Noncachexic patients with loss vs maintenance of adipose tissue demonstrated a higher ORR (64.7% vs 23.5%; P < .05) and longer PFS (18.5 vs 2.86 months; P = .037) in response to immunotherapy.

Study details: The data come from a single-center retrospective cohort study involving patients with advanced NSCLC (40 with cachexia and 34 without cachexia) who received programmed cell death-1/programmed cell death-ligand 1 inhibitors (pembrolizumab, nivolumab, or atezolizumab).

Disclosures: The study was funded by the Japan Agency for Medical Research and Development. The authors reported ties with one or more pharmaceutical companies outside this work.

Source: Nishioka N et al. Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer. Thorac Cancer. 2022;13(10):1496-1504 (Apr 14). Doi: 10.1111/1759-7714.14421

Key clinical point: Noncachexic patients with advanced nonsmall cell lung cancer (NSCLC) and adipose tissue loss may respond more favorably to immunotherapy.

Major finding: Cachexic patients with loss and maintenance of adipose tissue showed no significant differences in the objective response rate (ORR) and progression-free survival (PFS). Noncachexic patients with loss vs maintenance of adipose tissue demonstrated a higher ORR (64.7% vs 23.5%; P < .05) and longer PFS (18.5 vs 2.86 months; P = .037) in response to immunotherapy.

Study details: The data come from a single-center retrospective cohort study involving patients with advanced NSCLC (40 with cachexia and 34 without cachexia) who received programmed cell death-1/programmed cell death-ligand 1 inhibitors (pembrolizumab, nivolumab, or atezolizumab).

Disclosures: The study was funded by the Japan Agency for Medical Research and Development. The authors reported ties with one or more pharmaceutical companies outside this work.

Source: Nishioka N et al. Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer. Thorac Cancer. 2022;13(10):1496-1504 (Apr 14). Doi: 10.1111/1759-7714.14421

Key clinical point: The addition of nivolumab to neoadjuvant chemotherapy is more efficacious than and comparably safe compared to chemotherapy alone in patients with stage IB-IIIA resectable nonsmall cell lung cancer (NSCLC).

Major finding: The nivolumab plus chemotherapy vs chemotherapy-alone group demonstrated longer event-free survival (31.6 vs 20.8 months; hazard ratio 0.63; P = .005) and had a higher proportion of patients achieving pathological complete response (24.0% vs 2.2%; odds ratio 13.94; P < .001). The rates of grade 3/4 treatment-related adverse events were comparable between the groups (33.5% vs 36.9%).

Study details: The data come from an open-label phase 3 CheckMate 816 trial which included patients with resectable NSCLC who were randomly assigned to receive neoadjuvant nivolumab plus platinum-doublet chemotherapy (n = 179) or platinum-doublet chemotherapy alone (n = 179).

Disclosures: The trial was funded by Bristol Myers Squibb. The authors reported ties with one or more pharmaceutical companies outside this work, including Bristol Myers Squibb.

Source: Forde PM et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 (Apr 11). Doi: 10.1056/NEJMoa2202170

Key clinical point: The addition of nivolumab to neoadjuvant chemotherapy is more efficacious than and comparably safe compared to chemotherapy alone in patients with stage IB-IIIA resectable nonsmall cell lung cancer (NSCLC).

Major finding: The nivolumab plus chemotherapy vs chemotherapy-alone group demonstrated longer event-free survival (31.6 vs 20.8 months; hazard ratio 0.63; P = .005) and had a higher proportion of patients achieving pathological complete response (24.0% vs 2.2%; odds ratio 13.94; P < .001). The rates of grade 3/4 treatment-related adverse events were comparable between the groups (33.5% vs 36.9%).

Study details: The data come from an open-label phase 3 CheckMate 816 trial which included patients with resectable NSCLC who were randomly assigned to receive neoadjuvant nivolumab plus platinum-doublet chemotherapy (n = 179) or platinum-doublet chemotherapy alone (n = 179).

Disclosures: The trial was funded by Bristol Myers Squibb. The authors reported ties with one or more pharmaceutical companies outside this work, including Bristol Myers Squibb.

Source: Forde PM et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 (Apr 11). Doi: 10.1056/NEJMoa2202170

Key clinical point: The addition of nivolumab to neoadjuvant chemotherapy is more efficacious than and comparably safe compared to chemotherapy alone in patients with stage IB-IIIA resectable nonsmall cell lung cancer (NSCLC).

Major finding: The nivolumab plus chemotherapy vs chemotherapy-alone group demonstrated longer event-free survival (31.6 vs 20.8 months; hazard ratio 0.63; P = .005) and had a higher proportion of patients achieving pathological complete response (24.0% vs 2.2%; odds ratio 13.94; P < .001). The rates of grade 3/4 treatment-related adverse events were comparable between the groups (33.5% vs 36.9%).

Study details: The data come from an open-label phase 3 CheckMate 816 trial which included patients with resectable NSCLC who were randomly assigned to receive neoadjuvant nivolumab plus platinum-doublet chemotherapy (n = 179) or platinum-doublet chemotherapy alone (n = 179).

Disclosures: The trial was funded by Bristol Myers Squibb. The authors reported ties with one or more pharmaceutical companies outside this work, including Bristol Myers Squibb.

Source: Forde PM et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 (Apr 11). Doi: 10.1056/NEJMoa2202170

Key clinical point: A higher serum level of follicle-stimulating hormone (FSH) is an independent risk factor for rheumatoid arthritis (RA) and is positively associated with RA disease activity.

Major finding: Circulating FSH levels were significantly higher in women with RA vs age-matched healthy women (57.58 ± 15.94 vs 43.11 ± 19.46 mIU/mL; P = .025), with women with RA in the highest vs lowest quartiles of FSH levels having a significantly higher disease activity score of 28 joints with erythrocyte sedimentation rate (P < .001).

Study details: Findings are from a prospective analysis including 79 women with RA and 50 age-matched healthy women.

Disclosures: This study was supported by the Youth Foundation of Science and Technology Department of Shanxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Zhang X et al. High follicle-stimulating hormone level associated with risk of rheumatoid arthritis and disease activity. Front Endocrinol. 2022;13:862849 (Apr 22). Doi: 10.3389/fendo.2022.862849

Key clinical point: A higher serum level of follicle-stimulating hormone (FSH) is an independent risk factor for rheumatoid arthritis (RA) and is positively associated with RA disease activity.

Major finding: Circulating FSH levels were significantly higher in women with RA vs age-matched healthy women (57.58 ± 15.94 vs 43.11 ± 19.46 mIU/mL; P = .025), with women with RA in the highest vs lowest quartiles of FSH levels having a significantly higher disease activity score of 28 joints with erythrocyte sedimentation rate (P < .001).

Study details: Findings are from a prospective analysis including 79 women with RA and 50 age-matched healthy women.

Disclosures: This study was supported by the Youth Foundation of Science and Technology Department of Shanxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Zhang X et al. High follicle-stimulating hormone level associated with risk of rheumatoid arthritis and disease activity. Front Endocrinol. 2022;13:862849 (Apr 22). Doi: 10.3389/fendo.2022.862849

Key clinical point: A higher serum level of follicle-stimulating hormone (FSH) is an independent risk factor for rheumatoid arthritis (RA) and is positively associated with RA disease activity.

Major finding: Circulating FSH levels were significantly higher in women with RA vs age-matched healthy women (57.58 ± 15.94 vs 43.11 ± 19.46 mIU/mL; P = .025), with women with RA in the highest vs lowest quartiles of FSH levels having a significantly higher disease activity score of 28 joints with erythrocyte sedimentation rate (P < .001).

Study details: Findings are from a prospective analysis including 79 women with RA and 50 age-matched healthy women.

Disclosures: This study was supported by the Youth Foundation of Science and Technology Department of Shanxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Zhang X et al. High follicle-stimulating hormone level associated with risk of rheumatoid arthritis and disease activity. Front Endocrinol. 2022;13:862849 (Apr 22). Doi: 10.3389/fendo.2022.862849

Key clinical point: Acupuncture relieves pain and improves the health index in patients with rheumatoid arthritis (RA) and can be considered an adjunctive nonpharmacological treatment in rehabilitation programs.

Major finding: Invasive acupuncture vs control interventions significantly reduced pain (mean difference [MD] −1.00; P ­= .04), Health Assessment Questionnaire score (MD −0.20; P < .001), Physician Global Assessment score (MD ­−0.98; P < .001), tender joint count (MD ­−1.24; P ­= .005), C-reactive protein level (MD, −1.81; P =­ .019), and erythrocyte sedimentation rate (MD, −3.03; P =­ .032). Similar benefits were observed with laser acupuncture. No adverse events were reported.

Study details: This was a meta-analysis of 11 randomized controlled trials including 796 patients with RA, of which 402 received acupuncture therapy and 394 received control interventions.

Disclosures: The study was supported by Beijing Jishuitan Hospital Elite Young Scholar Programme, Beijing, China. The authors declared no conflicts of interest.

Source: Li H et al. Clinical efficacy of acupuncture for the treatment of rheumatoid arthritis: Meta-analysis of randomized clinical trials. Evid Based Complementary Altern Med. 2022;5264977 (Apr 30). Doi: 10.1155/2022/5264977

Key clinical point: Acupuncture relieves pain and improves the health index in patients with rheumatoid arthritis (RA) and can be considered an adjunctive nonpharmacological treatment in rehabilitation programs.

Major finding: Invasive acupuncture vs control interventions significantly reduced pain (mean difference [MD] −1.00; P ­= .04), Health Assessment Questionnaire score (MD −0.20; P < .001), Physician Global Assessment score (MD ­−0.98; P < .001), tender joint count (MD ­−1.24; P ­= .005), C-reactive protein level (MD, −1.81; P =­ .019), and erythrocyte sedimentation rate (MD, −3.03; P =­ .032). Similar benefits were observed with laser acupuncture. No adverse events were reported.

Study details: This was a meta-analysis of 11 randomized controlled trials including 796 patients with RA, of which 402 received acupuncture therapy and 394 received control interventions.

Disclosures: The study was supported by Beijing Jishuitan Hospital Elite Young Scholar Programme, Beijing, China. The authors declared no conflicts of interest.

Source: Li H et al. Clinical efficacy of acupuncture for the treatment of rheumatoid arthritis: Meta-analysis of randomized clinical trials. Evid Based Complementary Altern Med. 2022;5264977 (Apr 30). Doi: 10.1155/2022/5264977

Key clinical point: Acupuncture relieves pain and improves the health index in patients with rheumatoid arthritis (RA) and can be considered an adjunctive nonpharmacological treatment in rehabilitation programs.

Major finding: Invasive acupuncture vs control interventions significantly reduced pain (mean difference [MD] −1.00; P ­= .04), Health Assessment Questionnaire score (MD −0.20; P < .001), Physician Global Assessment score (MD ­−0.98; P < .001), tender joint count (MD ­−1.24; P ­= .005), C-reactive protein level (MD, −1.81; P =­ .019), and erythrocyte sedimentation rate (MD, −3.03; P =­ .032). Similar benefits were observed with laser acupuncture. No adverse events were reported.

Study details: This was a meta-analysis of 11 randomized controlled trials including 796 patients with RA, of which 402 received acupuncture therapy and 394 received control interventions.

Disclosures: The study was supported by Beijing Jishuitan Hospital Elite Young Scholar Programme, Beijing, China. The authors declared no conflicts of interest.

Source: Li H et al. Clinical efficacy of acupuncture for the treatment of rheumatoid arthritis: Meta-analysis of randomized clinical trials. Evid Based Complementary Altern Med. 2022;5264977 (Apr 30). Doi: 10.1155/2022/5264977

Key clinical point: Acupuncture relieves pain and improves the health index in patients with rheumatoid arthritis (RA) and can be considered an adjunctive nonpharmacological treatment in rehabilitation programs.

Major finding: Invasive acupuncture vs control interventions significantly reduced pain (mean difference [MD] −1.00; P ­= .04), Health Assessment Questionnaire score (MD −0.20; P < .001), Physician Global Assessment score (MD ­−0.98; P < .001), tender joint count (MD ­−1.24; P ­= .005), C-reactive protein level (MD, −1.81; P =­ .019), and erythrocyte sedimentation rate (MD, −3.03; P =­ .032). Similar benefits were observed with laser acupuncture. No adverse events were reported.

Study details: This was a meta-analysis of 11 randomized controlled trials including 796 patients with RA, of which 402 received acupuncture therapy and 394 received control interventions.

Disclosures: The study was supported by Beijing Jishuitan Hospital Elite Young Scholar Programme, Beijing, China. The authors declared no conflicts of interest.

Source: Li H et al. Clinical efficacy of acupuncture for the treatment of rheumatoid arthritis: Meta-analysis of randomized clinical trials. Evid Based Complementary Altern Med. 2022;5264977 (Apr 30). Doi: 10.1155/2022/5264977

Key clinical point: Acupuncture relieves pain and improves the health index in patients with rheumatoid arthritis (RA) and can be considered an adjunctive nonpharmacological treatment in rehabilitation programs.

Major finding: Invasive acupuncture vs control interventions significantly reduced pain (mean difference [MD] −1.00; P ­= .04), Health Assessment Questionnaire score (MD −0.20; P < .001), Physician Global Assessment score (MD ­−0.98; P < .001), tender joint count (MD ­−1.24; P ­= .005), C-reactive protein level (MD, −1.81; P =­ .019), and erythrocyte sedimentation rate (MD, −3.03; P =­ .032). Similar benefits were observed with laser acupuncture. No adverse events were reported.

Study details: This was a meta-analysis of 11 randomized controlled trials including 796 patients with RA, of which 402 received acupuncture therapy and 394 received control interventions.

Disclosures: The study was supported by Beijing Jishuitan Hospital Elite Young Scholar Programme, Beijing, China. The authors declared no conflicts of interest.

Source: Li H et al. Clinical efficacy of acupuncture for the treatment of rheumatoid arthritis: Meta-analysis of randomized clinical trials. Evid Based Complementary Altern Med. 2022;5264977 (Apr 30). Doi: 10.1155/2022/5264977

Key clinical point: Acupuncture relieves pain and improves the health index in patients with rheumatoid arthritis (RA) and can be considered an adjunctive nonpharmacological treatment in rehabilitation programs.

Major finding: Invasive acupuncture vs control interventions significantly reduced pain (mean difference [MD] −1.00; P ­= .04), Health Assessment Questionnaire score (MD −0.20; P < .001), Physician Global Assessment score (MD ­−0.98; P < .001), tender joint count (MD ­−1.24; P ­= .005), C-reactive protein level (MD, −1.81; P =­ .019), and erythrocyte sedimentation rate (MD, −3.03; P =­ .032). Similar benefits were observed with laser acupuncture. No adverse events were reported.

Study details: This was a meta-analysis of 11 randomized controlled trials including 796 patients with RA, of which 402 received acupuncture therapy and 394 received control interventions.

Disclosures: The study was supported by Beijing Jishuitan Hospital Elite Young Scholar Programme, Beijing, China. The authors declared no conflicts of interest.

Source: Li H et al. Clinical efficacy of acupuncture for the treatment of rheumatoid arthritis: Meta-analysis of randomized clinical trials. Evid Based Complementary Altern Med. 2022;5264977 (Apr 30). Doi: 10.1155/2022/5264977

Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.

Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).

Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.

Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.

Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003

Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.

Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).

Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.

Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.

Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003

Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.

Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).

Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.

Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.

Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003

Key clinical point: The risks for any serious bacterial, opportunistic, or herpes zoster infections were similar with add-on leflunomide or tacrolimus and tumor necrosis factor inhibitors (TNFi) in patients with seropositive rheumatoid arthritis (RA) receiving methotrexate.

Major finding: The risk for any serious infection was not significantly different with leflunomide (propensity score fine stratification-weighted hazard ratio [pHR, 1.03; 95% CI 0.89-1.22) or tacrolimus (pHR 0.91; 95% CI 0.77-1.08) compared to TNFi.

Study details: This was a population-based cohort study including 72,516 patients with seropositive RA who were taking methotrexate, of which 20,262 patients initiated leflunomide, tacrolimus, or TNFi therapy.

Disclosures: This study was supported by an investigator-sponsored grant from Hanlim pharmaceutical company. The authors declared no conflicts of interest.

Source: Shin A et al. Semin Arthritis Rheum. 2022 Apr 28. doi: 10.1016/j.semarthrit.2022.152019.

Key clinical point: The risks for any serious bacterial, opportunistic, or herpes zoster infections were similar with add-on leflunomide or tacrolimus and tumor necrosis factor inhibitors (TNFi) in patients with seropositive rheumatoid arthritis (RA) receiving methotrexate.

Major finding: The risk for any serious infection was not significantly different with leflunomide (propensity score fine stratification-weighted hazard ratio [pHR, 1.03; 95% CI 0.89-1.22) or tacrolimus (pHR 0.91; 95% CI 0.77-1.08) compared to TNFi.

Study details: This was a population-based cohort study including 72,516 patients with seropositive RA who were taking methotrexate, of which 20,262 patients initiated leflunomide, tacrolimus, or TNFi therapy.

Disclosures: This study was supported by an investigator-sponsored grant from Hanlim pharmaceutical company. The authors declared no conflicts of interest.

Source: Shin A et al. Semin Arthritis Rheum. 2022 Apr 28. doi: 10.1016/j.semarthrit.2022.152019.

Key clinical point: The risks for any serious bacterial, opportunistic, or herpes zoster infections were similar with add-on leflunomide or tacrolimus and tumor necrosis factor inhibitors (TNFi) in patients with seropositive rheumatoid arthritis (RA) receiving methotrexate.

Major finding: The risk for any serious infection was not significantly different with leflunomide (propensity score fine stratification-weighted hazard ratio [pHR, 1.03; 95% CI 0.89-1.22) or tacrolimus (pHR 0.91; 95% CI 0.77-1.08) compared to TNFi.

Study details: This was a population-based cohort study including 72,516 patients with seropositive RA who were taking methotrexate, of which 20,262 patients initiated leflunomide, tacrolimus, or TNFi therapy.

Disclosures: This study was supported by an investigator-sponsored grant from Hanlim pharmaceutical company. The authors declared no conflicts of interest.

Source: Shin A et al. Semin Arthritis Rheum. 2022 Apr 28. doi: 10.1016/j.semarthrit.2022.152019.

Key clinical point: Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Key clinical point: Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Key clinical point: Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Key clinical point: Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Key clinical point: Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Key clinical point: Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Key clinical point: Treatment with tofacitinib, tocilizumab, or tumor necrosis factor inhibitors (TNFi) vs. abatacept did not reduce the risk of developing Alzheimer disease and related dementia (ADRD) in patients with rheumatoid arthritis (RA).

Major finding: The risk for ADRD associated with tofacitinib (adjusted hazard ratio [aHR] 0.90; 95% CI 0.55-1.51), tocilizumab (aHR 0.82; 95% CI 0.55-1.21), and TNFi (aHR 0.93; 95% CI 0.72-1.20) was similar to that with abatacept.

Study details: This was an observational study including 22,569 patients aged ≥65 years with RA from the DREAM study who were treated with tofacitinib, tocilizumab, or TNFi and were propensity score-matched with an equal number of patients treated with abatacept.

Disclosures: The DREAM study is funded by the National Institute on Aging. Several authors reported receiving grants, personal fees, or salary support from or owning stocks in various sources outside the submitted work.

Source: Desai RJ et al. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents. JAMA Netw Open. 2022;5(4):e226567 (Apr 8). Doi: 10.1001/jamanetworkopen.2022.6567

Key clinical point: Treatment with tofacitinib, tocilizumab, or tumor necrosis factor inhibitors (TNFi) vs. abatacept did not reduce the risk of developing Alzheimer disease and related dementia (ADRD) in patients with rheumatoid arthritis (RA).

Major finding: The risk for ADRD associated with tofacitinib (adjusted hazard ratio [aHR] 0.90; 95% CI 0.55-1.51), tocilizumab (aHR 0.82; 95% CI 0.55-1.21), and TNFi (aHR 0.93; 95% CI 0.72-1.20) was similar to that with abatacept.

Study details: This was an observational study including 22,569 patients aged ≥65 years with RA from the DREAM study who were treated with tofacitinib, tocilizumab, or TNFi and were propensity score-matched with an equal number of patients treated with abatacept.

Disclosures: The DREAM study is funded by the National Institute on Aging. Several authors reported receiving grants, personal fees, or salary support from or owning stocks in various sources outside the submitted work.

Source: Desai RJ et al. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents. JAMA Netw Open. 2022;5(4):e226567 (Apr 8). Doi: 10.1001/jamanetworkopen.2022.6567

Key clinical point: Treatment with tofacitinib, tocilizumab, or tumor necrosis factor inhibitors (TNFi) vs. abatacept did not reduce the risk of developing Alzheimer disease and related dementia (ADRD) in patients with rheumatoid arthritis (RA).

Major finding: The risk for ADRD associated with tofacitinib (adjusted hazard ratio [aHR] 0.90; 95% CI 0.55-1.51), tocilizumab (aHR 0.82; 95% CI 0.55-1.21), and TNFi (aHR 0.93; 95% CI 0.72-1.20) was similar to that with abatacept.

Study details: This was an observational study including 22,569 patients aged ≥65 years with RA from the DREAM study who were treated with tofacitinib, tocilizumab, or TNFi and were propensity score-matched with an equal number of patients treated with abatacept.

Disclosures: The DREAM study is funded by the National Institute on Aging. Several authors reported receiving grants, personal fees, or salary support from or owning stocks in various sources outside the submitted work.

Source: Desai RJ et al. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents. JAMA Netw Open. 2022;5(4):e226567 (Apr 8). Doi: 10.1001/jamanetworkopen.2022.6567